LODOCO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LODOCO (LODOCO).
Colchicine binds to tubulin, inhibiting microtubule polymerization, which disrupts mitosis and reduces inflammatory cell chemotaxis, adhesion, and activation. It also inhibits NLRP3 inflammasome assembly and IL-1β production.
| Metabolism | Primarily metabolized by hepatic CYP3A4 and to a lesser extent by CYP2D6; also undergoes deacetylation and demethylation. |
| Excretion | Primarily renal (approximately 50-70% as unchanged drug), with biliary/fecal elimination accounting for 20-30%. |
| Half-life | Terminal half-life: approximately 18-24 hours in patients with normal renal function. |
| Protein binding | Low; approximately 10-30% bound to albumin. |
| Volume of Distribution | Approximately 2-5 L/kg, indicating extensive tissue distribution, particularly in leukocytes. |
| Bioavailability | Oral bioavailability is approximately 25-45% (high first-pass metabolism). |
| Onset of Action | Oral: Onset of colchicine's anti-inflammatory effect typically occurs within 12-24 hours; intravenous (not common): faster onset, within a few hours. |
| Duration of Action | Anti-inflammatory effect persists for 24-48 hours after a single dose; therapeutic effect for gout flares lasts up to 48 hours. |
0.5 mg orally twice daily.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for GFR ≥15 mL/min. For GFR <15 mL/min, reduce dose to 0.5 mg once daily. |
| Liver impairment | Child-Pugh Class A and B: no adjustment. Child-Pugh Class C: not recommended due to lack of data. |
| Pediatric use | Not approved for use in pediatric patients younger than 18 years. |
| Geriatric use | No specific dose adjustment; use with caution due to increased sensitivity to hypotension and bradycardia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LODOCO (LODOCO).
| Breastfeeding | Colchicine is excreted into human breast milk. The milk-to-plasma ratio is approximately 1:1. Peak milk concentrations occur 1-2 hours after maternal dose. Relative infant dose is estimated at 10-15% of maternal weight-adjusted dose. Potential adverse effects in nursing infants include diarrhea and vomiting. Breastfeeding is not recommended during colchicine therapy due to the risk of toxicity in the infant. |
| Teratogenic Risk | Colchicine (Lodoco) is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Animal studies have shown teratogenic effects at doses equivalent to human therapeutic doses. First trimester exposure may be associated with an increased risk of neural tube defects. Second and third trimester risks include possible fetal growth restriction and developmental delays. Use only if potential benefit justifies potential risk to the fetus. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to colchicine","Severe renal impairment (CrCl <10 mL/min)","Severe hepatic impairment","Concomitant use of strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) in patients with renal or hepatic impairment","Concomitant use of P-glycoprotein inhibitors (e.g., cyclosporine) in patients with renal or hepatic impairment"]
| Precautions | ["Severe hematologic toxicity (myelosuppression, leukopenia, thrombocytopenia)","Neuromuscular toxicity (especially with renal impairment or concomitant statins)","Severe gastrointestinal toxicity (diarrhea, nausea, vomiting)","Drug interactions (CYP3A4 and P-glycoprotein inhibitors)","Hepatic impairment","Renal impairment"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal complete blood count (CBC), liver function tests (LFTs), and renal function periodically due to colchicine toxicity risk. During pregnancy, monitor fetal growth with serial ultrasounds given potential for growth restriction. Assess for signs of gastrointestinal toxicity (nausea, vomiting, diarrhea) in the mother. Fetal monitoring for neural tube defects via maternal serum alpha-fetoprotein and ultrasound at 16-20 weeks if exposed in first trimester. |
| Fertility Effects | Colchicine may impair spermatogenesis and cause azoospermia or oligospermia in males, which is usually reversible upon discontinuation. In females, case reports suggest possible ovarian toxicity and menstrual irregularities. Reversible infertility may occur. Advise men and women of reproductive potential to use effective contraception during therapy and for at least 3 months after discontinuation. |